Longeveron KOL Event: Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™
About The Event
Join us for a virtual KOL event with Longeveron, featuring Sunjay Kaushal, MD, PhD (Northwestern University Feinberg School of Medicine & Division Head, Cardiovascular and Thoracic Surgery at Lurie Children’s Hospital) and Ram Kumar Subramanyan, MD, PhD (USC Keck School of Medicine) who will discuss the unmet medical need and current standard of care for patients suffering from Hypoplastic Left Heart Syndrome (HLHS), as well as the potential for Medicinal Signaling Cells (MSCs), such as those making up Longeveron’s Lomecel-B™ injection, in potentially improving the outcome for these patients.
Joshua Hare, MD, Longeveron Co-Founder and Chief Scientific Officer, and Wa’el Hashad, Longeveron Chief Executive Officer, will provide insight into the Phase 2 ELPIS II trial evaluating the efficacy of Lomecel-B™ in conjunction with reconstructive surgeries compared to surgeries alone for HLHS. Company leadership will provide a pipeline update and insight into future directions.
A question and answer session will follow the formal presentation. Please submit your questions prior to the event date.